Use-case library

One engine. 100 ranked decision questions.

Start from the question, not a blank canvas. Every use case ships with an executive brief, a detailed dossier and a recipe that builds the board in one click: the filters, the signature exhibit and the board are set for you.

Across eight functions

Built for the specialists who prepare the call.

CI, R&D, BD, market research and strategy teams build their own views on the same engine.

R&D / Discovery
16
Business development & licensing
15
Market access & HEOR
14
Marketing & sales
12
Regulatory affairs
11
Medical affairs
11
Pharmacovigilance & safety
11
Clinical operations
10
Top of the ranking
  • 1
    Indication prioritisationHow crowded or open is a therapeutic area before we commit?
    R&D · Bullseye
  • 4
    Deal timing intelligenceWhen should BD move, given the competitive timeline?
    BD · Timeline
  • 5
    Unmet-need whitespaceWhere is the burden high and the field still thin?
    BD · Quadrant map
  • 6
    Approved-product & label landscapeWhat is already approved, and on what label?
    Marketing · Bullseye
  • 8
    Asset 360 diligenceWho owns the asset, and what do trials, IP and filings show?
    BD · Ownership tree
  • 10
    Regulatory intelligence monitoringWhat changed in the regulatory landscape for our area?
    RA · Diff view

Lead views across the 100 use cases span 24 chart types; bullseye and timeline lead 38 of them. Weighted score = 0.30 stakes + 0.25 centrality + 0.15 reach + 0.15 frequency + 0.15 data fit. You can re-weight the ranking for your own priorities.

Key questions on real data

Three answers a GI team gets today.

ClinicalTrials.gov, pulled 11 September 2026. Re-run the recipe and the answer updates; freeze it and it doesn't.

Competitive landscape

UC and Crohn's absorb 157 of 169 active GI trials

Crowded: 63 of the 157 IBD trials are already in Phase 3. Thin: celiac disease has five trials and none in Phase 3. An opportunity to qualify against disease burden and terminated trials, not yet white space.

Early warning

Six of nine active EoE trials reach primary completion in 2026

Plan site activation for H1 2027 and watch the Phase 3 whose completion date has passed with its status unchanged.

Opportunity detection

Germany pairs deep Crohn's experience with light competition

2.3 competing trials per 10 completed, against 20.0 in China. Shortlist Germany; pair Poland and Spain with enrolment-risk monitoring.

See the charts on the home page
Clinical trials offering

Ten ranked clinical-operations questions, feasibility to capacity.

Each one ships with a brief, a dossier and a recipe that builds the board. The lead view is the best-fit chart for the decision.

CO-01

Feasibility assessment

Where are similar trials already running?

Experience vs competition
CO-02

Site selection

Which sites hold established patient pools?

Concentration (Pareto)
CO-03

Recruitment benchmarking

What enrolment rate is realistic?

Distribution vs benchmark
CO-04

Protocol design benchmarking

Where does our protocol deviate from the field?

Eligibility waterfall
CO-05

Competitive enrolment risk

Who is recruiting our patients right now?

Diverging bar by region
CO-06

Country entry strategy

Where do infrastructure and precedent exist?

Action-zone map
CO-07

Timeline planning

When do competing trials finish?

Timeline
CO-08

CRO & vendor landscape

Who runs this work in the region?

Concentration (Pareto)
CO-09

Termination risk

Why do trials in our area stop?

Ranked bar by reason
CO-10

Capacity planning

Which sites are already saturated?

KPI snapshot
Worked examples

Landscapes already built, across therapeutic areas.

Every instance comes with worked examples, so your team starts from a finished board rather than an empty one.

Melanoma immunotherapyR&D Alzheimer's Phase 2R&D Rare disease gene therapyR&D Bispecific antibodiesBD ADC oncology partnersBD Cell therapy licensingBD Atopic dermatitis outcomesMarket access Heart failure real worldMarket access Diabetes cardiovascularMarket access Psoriasis competitiveMarketing NSCLC biomarkersMarketing IBD biologicsMarketing Paediatric rare diseaseRegulatory Biosimilar insulinRegulatory Digital therapeuticsRegulatory Multiple sclerosis evidenceMedical affairs Asthma biologicsMedical affairs Obesity GLP-1Medical affairs

Which question would you ask first?

Bring it to a pilot and get the answer on your own programme.

Plan a pilot